key: cord-0953545-8oydo2b9 authors: Hanna, Catherine R.; Robb, Kathryn A.; Blyth, Kevin G.; Jones, Robert J.; Chalmers, Anthony J. title: Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease date: 2020-12-10 journal: Int J Radiat Oncol Biol Phys DOI: 10.1016/j.ijrobp.2020.12.003 sha: 630d3c105888b007c1e261e01dcefe1a8e0c43e2 doc_id: 953545 cord_uid: 8oydo2b9 Introduction Current treatments for COVID-19 lung disease have limited efficacy. Low dose radiotherapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we explored clinicians’ perspectives in order to identify barriers to testing LDRT in clinical trials and implementing it in clinical practice. Methods Semi-structured interviews were undertaken with six clinicians from three medical disciplines. Interviews were recorded, transcribed verbatim and analysed thematically, using a framework approach. Common themes regarding barriers to using LDRT for COVID-19 lung disease were identified from the data. Results Three categories of barriers emerged: i) the potential to do harm to the patient, including difficulty in predicting harm and lack of existing data to inform quantification of risks; ii) the feasibility of trialling this novel treatment strategy in the clinical setting, in particular patient selection and buy-in from relevant clinician groups; and iii) the logistics of delivering the treatment, in particular risks of transmission to other patients and resources required for patient transfer. Conclusions This study identified several barriers that may impede the evaluation and subsequent implementation of LDRT as a treatment for COVID-19 lung disease, from the perspectives of clinicians in three relevant specialties. By documenting and articulating these concerns, we hope to enhance discussion of why these barriers exist, and enable them to be addressed in a proactive manner in order to facilitate research into the potential benefits of radiation treatment for patients with COVID-19 lung disease. 1 Title: Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease Abstract Introduction Current treatments for COVID-19 lung disease have limited efficacy. Low dose radiotherapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we explored clinicians' perspectives in order to identify barriers to testing LDRT in clinical trials and implementing it in clinical practice. Semi-structured interviews were undertaken with six clinicians from three medical disciplines. Interviews were recorded, transcribed verbatim and analysed thematically, using a framework approach. Common themes regarding barriers to using LDRT for COVID-19 lung disease were identified from the data. Three categories of barriers emerged: i) the potential to do harm to the patient, including difficulty in predicting harm and lack of existing data to inform quantification of risks; ii) the feasibility of trialling this novel treatment strategy in the clinical setting, in particular patient selection and buy-in from relevant clinician groups; and iii) the logistics of delivering the treatment, in particular risks of transmission to other patients and resources required for patient transfer. The Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) is having an unprecedented health and societal impact, with over 54 million cases and 1.3 million deaths reported globally (1) . Patients with SARS-CoV-2 who develop severe pneumonia and acute respiratory distress syndrome (ARDS) have the highest mortality rates (2) . The lung pathology is characterised by diffuse alveolar damage suggestive of ARDS with alveolar infiltration by immune cells and pro-inflammatory cytokines (3) (4) (5) . Research efforts to find effective treatments have included evaluation of low-dose radiation therapy (LDRT) with the rationale that LDRT has anti-inflammatory and immunemodulatory effects which may counteract the pro-inflammatory state observed in SARS-CoV2 infected patients (5, 6) . Initiation of clinical trials to test LDRT has been slow, with preliminary results from two studies treating a total of 10 patients reported to date (7, 8) . Individuals and groups within the radiation oncology community have expressed concerns over the acceptability and validity of using radiation therapy in this context (9, 10) . Better understanding of clinicians' concerns over the use of LDRT for COVID-19 lung disease would enable these issues to be addressed proactively, facilitating high quality research in this field. In this study we aimed to identify and characterise these concerns by investigating multidisciplinary clinician perspectives on the topic. Semi-structured interviews were undertaken by one researcher in July and August 2020. Potential participants were consultant level medical professionals working in the UK National Health Service within the disciplines of radiation oncology, intensive care or respiratory medicine. These specialities were chosen to represent clinicians involved in treating patients with COVID-19 lung disease and/or responsible for delivering radiation treatment. A convenience sample, identified by members of the J o u r n a l P r e -p r o o f research team, was initially approached. Initially, there were two replies out of six individuals approached. A snowballing technique, whereby clinicians who participated or declined were asked to identify alternative participants, was used. In this way, a further seven clinicians were approached and four of these agreed to participate. In total, thirteen clinicians were invited and six agreed to be interviewed (3 men: 3 women) with representation from all three medical disciplines (2 of each). The interviews were recorded using video conferencing, and the audio recordings transcribed verbatim. Thematic analysis (11) using a framework approach (12) was undertaken by two researchers (XXX, XXX) who each coded all of the interviews. Codes and themes were developed deductively and iteratively refined after coding each interview via comparison of coding outcomes and discussion of discrepancies. Microsoft Excel® 2016 was used for all analyses. Three broad categories of barriers to using and testing LDRT for COVID-19 emerged from the interviews ( Figure 1S in Supplementary File 1): i) potential to do harm; ii) feasibility of clinically trialling this novel treatment strategy ("trialablity"); and iii) logistics of treatment delivery. The key opinions from each participant are summarised in Table 1 There was concern that LDRT could make an inflammatory state worse and that predicting the likelihood of this harm would be difficult. Radiation oncology participants in particular were concerned that it would not be possible to test patients' lung function accurately, which is normal practice prior to prescribing radiotherapy for lung cancer. Some interviewees were reassured by the low radiation dose being used; others felt that the risk of exacerbating an inflammatory state worse was likely to be idiosyncratic and not dose dependent. Opinions were mixed over whether the lungs J o u r n a l P r e -p r o o f were the optimal target. One ICU and one respiratory consultant agreed with treating the lungs whereas one clinical oncologist favoured targeting lymphoid organs. There was a consistent opinion that assessing the risk/benefit balance was especially difficult because of the novelty of the treatment and the apparent lack of supporting data. It was highlighted that previous reports of using LDRT to treat pneumonia, both contemporary and historical, did not fully allay concerns over potential harms. Participants discussed the challenge of designing a clinical trial with meaningful end-points to measure treatment benefit, and of obtaining an adequate sample size. The primary end-points suggested by these participants included mortality, specifically in line with the RECOVERY trial endpoint, as well as an endpoint that would measure a reduction in oxygen requirement. Several clinicians were of the opinion that the benefit would need to be large for two reasons: to be able to detect it within a clinical trial (especially if patient numbers were small), and to support a change in practice. Participants were aware of preliminary data testing LDRT for COVID-19 lung disease in a small number of patients. Nevertheless, they noted that early phase trials may not be large enough to provide reassurance regarding potential harms, and that proving efficacy of LDRT over standard care would be difficult since a proportion of patients would recover spontaneously. Difficulties in predicting future prevalence of COVID-19 and how this might affect recruitment to a clinical trial testing LDRT were also highlighted. Despite this, there was general agreement that it was easier to initiate and recruit to COVID-19 trials compared to trials in other disease types. Secondly, the challenge of ensuring "buy-in" from clinicians was noted, especially given the novelty of the intervention and the perceived comparison to drug treatments being tested in competing trials. It was highlighted that the medical professional recruiting patients would likely be a respiratory physician and/or intensivist who is not familiar with radiotherapy, whereas the clinician J o u r n a l P r e -p r o o f delivering the treatment would be a radiation oncologist. This was considered unusual for a clinical trial and posed challenges regarding multi-disciplinary working, communication and trust. Finally, the challenge of understanding which patients would or would not be optimal candidates for a trial was identified. No specific age cut-off was identified, and although obesity and ethnicity were mentioned as important patient related risk factors, there was no consensus that these would be sufficient for patient selection. One of the respiratory physicians was aware of preliminary data from the RESCUE 1-19 trial which recruited mainly older patients and expressed reassurance that including older patients in future trials would be acceptable. There was agreement around excluding patients with underlying lung disease, additional reasons for hypoxaemia such as pulmonary embolism or requiring intensive care level medical support. These were all identified as factors that would increase the likelihood of harm as well as difficulties delivering treatment. Considering this dilemma, some clinicians suggested that optimal candidates might be those requiring level 2 hospital care, with a moderate oxygen requirement on approximately day 10 of the disease trajectory. The final barriers that emerged were logistical. A major focus was the transfer of patients from medical wards to a radiotherapy department and, aside from the potential harm caused, the practicalities of performing that transfer within current resource levels. Comments related to the lack of higher level (ICU) support on radiotherapy sites and risk of transmission to other patients in the radiotherapy department. Lastly, the ability to implement LDRT in a "real world" setting in terms of resources, cost and scalability was seen as a barrier, even if it were shown to be effective in clinical trials. This is the first study to capture clinician attitudes to the use of LDRT for COVID-19 lung disease. Our findings have implications for researchers evaluating the role of LDRT in COVID-19 lung disease and physicians considering its implementation in clinical practice. Specifically, there was apprehension around aggravating pulmonary inflammation and a lack of evidence to inform the likelihood of this occurring. Emerging safety data from ongoing early phase trials and appropriate patient selection, informed by knowledge of previous lung pathology and/or radiological evaluation of baseline lung damage, will help to address this concern. Increasing understanding of the COVID-19 disease trajectory and data from control arms of ongoing randomised trials, will also support identification of meaningful endpoints for larger scale clinical trials. The concern regarding the distinction between the recruiting versus treating clinician raises an important point about the uniqueness of using radiation treatment for a non-malignant condition and indicates that robust inter-disciplinary relationships will be required for successful set-up and running of a LDRT/COVID-19 trial. Finally, logistical concerns would need to be proactively addressed. The risk of transmission is not unique to radiation therapy but there are specific challenges associated with vulnerable cancer patients receiving treatment in the same departments. Also, radiotherapy infrastructure is well developed in many countries but not always co-located with acute/intensive care facilities and capacity to treat additional, non-cancer patients may be limited. Participants in this study suggested that appropriate primary endpoints for a trial to investigate LDRT for COVID-19 lung disease would be mortality or a reduction in oxygen requirement. Future research is required to investigate what magnitude of benefit would need to be demonstrated in a clinical trial to support implementation of LDRT in real world setting. Our study participants made clear that any trial conducted to investigate LDRT may compete with trials assessing drug treatments, and that patients receiving LDRT in the context of a clinical trial would very likely already be receiving steroids, given the results of the RECOVERY trial (13) . It would be particularly interesting to J o u r n a l P r e -p r o o f investigate how clinicians envisage LDRT would be used alongside other potential therapies such as steroids and anti-virals, and if the benefit from LDRT would need to be at least equivalent to benefits seen for other novel therapies to be used in practice. Our study has limitations. Firstly, study participants were all from one location and it is unclear if the same barriers exist globally. If they do, it would be informative to understand how they were addressed and overcome in those centres where trials have opened (14) . This raises a broader question about variation in risk attitudes in the context of novel therapies between healthcare systems or geographical regions. We were not surprised that results from current trials were not commonly discussed, considering the findings from only one pilot study (n=5) were published at the time the interviews were conducted. Secondly, only two clinicians were interviewed from each discipline. The notion of sample size and data saturation within qualitative research remains much debated (15) . The study was not intended to be a comprehensive investigation of all possible attitudes to LDRT for COVID-19 lung disease, but rather a pragmatic, yet informative and timely approach to explore common themes from interviewing a purposive sample of clinicians. Lastly, we did not seek the patient perspective on using LDRT for COVID-19 lung disease but appreciate this to be an important, complementary avenue of research. In conclusion, we recognised the difficulty of setting up a multi-disciplinary study investigating a novel therapy within the field of radiation oncology and have demonstrated the value of conducting a qualitative study to determine the feasibility and acceptability of this research. Specifically, we have identified the main barriers to the use of LDRT for COVID-19. Open discussion of these barriers will facilitate high quality research in this field. Future research could build on the results from this study by using a more quantitative approach to investigate the magnitude of benefit that would be required from a clinical trial investigating LDRT for COVID-19 in order to change clinical practice. -Radiation oncologists deliver treatment, therefore responsible for any harm caused. -Idiosyncratic lung damage from LDRT likely. -Low dose unlikely to cause harm in majority of patients. -Concern: pneumonitis. -Lungs a reasonable target. -Not doing harm bigger priority than knowing the treatment works. -Harm may be caused by transfer. -Imaging of lungs prior to treatment advised. -Potential harms around transfer. -Potential harm from worsening hypoxia. -Thinks colleagues may have concerns about lung damage. -Open to the concept that LDRT will reduce inflammation. -Agrees with lungs as target. -Concerns regarding transfer. -Some reassurance from low dose. -Not reassured by contemporary data due to low patient numbers. -Changing landscape regarding COVID-19 treatments. -Even if small trials done, not sufficient patient numbers to reassure regarding harm. -Trial data would important to provide reassurance around harms. -Current lack of evidence around the longer term effects of COVID on the lungs. -Aware of recent trial evidence. -Lack of personal experience with radiotherapy for non-malignant condition. -Lack of information around the longer term effects of COVID-19. -Lack of personal experience with radiotherapy treatments. -Some reassurance regarding the low dose used after reviewing previous literature on using LDRT -Clinician buy-in reduced due to the potential harm caused by LDRT. -Competition with other novel treatments for COVID-19. -Understanding how radiotherapy works in non-malignant condition. -Competition with other clinical trials testing novel treatments for COVID-19. -Most clinicians see value in researching new treatments due to the lack of proven therapies. -Reduced clinician buy-in due to extra workload/fear of the unknown when it comes to radiotherapy. -Open to the idea of trialling LDRT and agreement with the potential biological plausibility. -Not doing harm vs risk in patients with no other options/those who recover spontaneously. -Avoid patients with unhealthy lungs who are very unwell. -Obesity a risk factor. -Avoid LDRT in young, fit patients who may recover spontaneously and those with lung fibrosis. -Obesity risk factor for poor outcomes for COVID-19. -Avoid LDRT in early phase of the disease when patients well as may recover spontaneously. -Exclude underlying lung disease/acute conditions that worsen hypoxia (PE). -Target those starting to deteriorate/ oxygen requirement/requiring level 2 care/day 10-14. -Avoid in patients on CPAP/very high levels of oxygen: logistics of transfer and treatment delivery difficult. -Avoid intubated patients/level 3 care. -Those requiring level 2/HDU care reasonable. -Many will recover spontaneously. Logistics Transfer -Staffing required for safe transfer to radiotherapy department. -Time spent in the radiotherapy department and potential for deterioration during transfer. -Logistics of treatment delivery. -Difficulty transporting unwell patients on oxygen. -Staff required for transfer/ potential waiting time in the radiotherapy department. -Staffing required for transfer -Effect on other departments. -Transferring unwell patients and the effects on staffing. -Compared to other COVID-19 trials, transfer an extra issue. -Staff/patients at risk of transmission. -Related to time spent by patients in radiotherapy department. -Logistics of separate rooms for COVID-19 positive patients/risk of transmission to others in transit. -Staff/patient transmission. -Cancer patients particularly vulnerable. -Logistics of separating COVID-19 positive patients from non-COVID patients. -Transmission risk during patient transfer from previous experience. -Implementation of LDRT would siphon resources away from other departments and patients. -Versus steroids, LDRT more difficult to scale up to population level. -Potentially large pool of patients who eligible if shown to be effective. -Resource implications for implementation of this treatment would be important. WHO Coronavirus Disease (COVID-19) Dashboard 2020 Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine COVID-19: immunopathology and its implications for therapy COVID-19: consider cytokine storm syndromes and immunosuppression Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure Abstract PO-093: Low-dose whole-lung radiation for COVID-19 pneumonia: Planned day-7 interim analysis of a registered clinical trial Low-Dose Whole-Lung Irradiation for COVID-19 Pneumonia: Short Course Results Personal View: Low-dose Lung Radiotherapy for COVID-19 Pneumonia -The Atypical Science and the Unknown Collateral Consequence Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Introducing Qualitative Research: A student's guide to the craft of doing qualitative research Qualitative research in health care. Analysing qualitative data Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiation research To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales Nil Author information: